reports
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and...
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024 Dosed second pediatric patient in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 pediatric trial in Q1 2024 FDA granted Regenerative Medicine Advanced Therapy designation fol...
Landmark Bancorp Inc: 1 director
A director at Landmark Bancorp Inc bought 1,050 shares at 18.961USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Taysha Gene Therapies to Release First Quarter 2024 Financial Results ...
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14 DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024, and host a corporate update conference call and webcast on Tuesday, May 14, 2024, at 4:30 PM Eastern T...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 528,000 shares of the Company's common stock in connection with their emp...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support the potential expedited development and review of TSHA-102 in clinical evaluation for Rett syndrome DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Na...
Landmark Bancorp, Inc. Announces First Quarter Earnings Per Share of $...
Landmark Bancorp, Inc. Announces First Quarter Earnings Per Share of $0.51. Declares Cash Dividend of $0.21 per Share Manhattan, KS, May 01, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.51 for the three months ended March 31, 2024, compared to $0.48 per share in the fourth quarter of 2023 and $0.61 per share in the same quarter last year. Net earnings for the first quarter of 2024 amounted to $2.8 million, compared to $2.6 million in the prior quarter and $3.4 million for the first quarter of 2023. For the three month...
Landmark Bancorp, Inc. Announces Conference Call to Discuss First Quar...
Landmark Bancorp, Inc. Announces Conference Call to Discuss First Quarter 2024 Earnings Manhattan, KS, April 25, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (Nasdaq: LARK) announced that it will release earnings for the first quarter of 2024 after the market closes on Wednesday, May 1, 2024. The Company will host a conference call to discuss these results on Thursday, May 2, 2024 at 10:00 am (CT). Investors may listen to the Company’s earnings call via telephone by dialing (833) 470-1428 and using access code 688391. Investors are encouraged to call the dial-in number at least 5 minut...
Calavo Growers, Inc. Provides Update to Shareholders
Calavo Growers, Inc. Provides Update to Shareholders SANTA PAULA, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Calavo Growers, Inc. (Nasdaq: CVGW) (“Calavo” or the “Company”), a global avocado industry leader and provider of convenient, ready-to-eat fresh food, yesterday at its Annual Meeting of Shareholders said in a business update that: The Company has made significant progress toward completing the proposed sale of the Fresh Cut business (formerly “RFG”) and related real property and expects to close in May 2024As previously shared, the expected uses of sale proceeds would include payi...
Calavo Growers, Inc. to Provide General Business Update at 2024 Annual...
Calavo Growers, Inc. to Provide General Business Update at 2024 Annual Meeting of Shareholders SANTA PAULA, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Calavo Growers, Inc. (Nasdaq: CVGW) (“Calavo” or the “Company”), a global avocado industry leader and provider of convenient, ready-to-eat fresh food, announced today that following the formal business of the 2024 annual shareholder meeting (the “Annual Meeting”), the Company will provide a general business update. The Annual Meeting will be held at 1:00 p.m. Pacific Time on Wednesday, April 24, 2024. Holders of record at the close of busi...
Calavo Growers, Inc. Announces Virtual Access for its 2024 Annual Meet...
Calavo Growers, Inc. Announces Virtual Access for its 2024 Annual Meeting of Shareholders SANTA PAULA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CVGW) (“Calavo” or the “Company”), a global avocado-industry leader and provider of convenient, ready-to-eat fresh food, today reminded shareholders that the Company will provide its shareholders with the capability to attend its 2024 annual shareholder meeting (the “Annual Meeting”) virtually. The Annual Meeting will consist of a formal business meeting only. The Company is offering the virtual alternative as a way for shareholders to...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with thei...
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Pro...
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six Data from second adult patient showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 19-week assessment, with sustained improvement acro...
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Pro...
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a c...
Calavo Growers, Inc. Announces First Quarter 2024 Financial Results
Calavo Growers, Inc. Announces First Quarter 2024 Financial Results SANTA PAULA, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global avocado industry leader and provider of convenient, ready-to-eat fresh food, today reported its financial results for the fiscal first quarter ended January 31, 2024. First Quarter Financial Overview Introductory Note: In the first quarter of 2024, we concluded that the fresh cut (formerly RFG) business meets the requirements to be classified as held for sale and discontinued operations. As a result, the financial results of that busin...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on March 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company's common stock in connection with their...
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program i...
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company’s request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in Q2 2024 REVEAL adolescent and adult trial will now expand into the U.S. following submission to FDA (age 12+ protocol) Dosing of second patient in cohort one (low dose) of REVEAL pediatric trial expected in Q1 2024 following Independent Data Monitoring Committee ...
Calavo Growers to Report First Quarter Financial Results
Calavo Growers to Report First Quarter Financial Results SANTA PAULA, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in the avocado and value-added fresh food industries, today announced that it will release financial results for the fiscal first quarter ended January 31, 2024, after the market closes on Monday, March 11. About Calavo Growers, Inc. Calavo Growers, Inc. (Nasdaq: CVGW) is a global leader in quality produce, including avocados, tomatoes and papayas, and a pioneer of healthy fresh-cut fruit, vegetables and prepared foods. Calavo products are so...
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Progra...
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development. Taysha has been working to find ways to advance its deprioritized programs. On ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that, on February 1, 2024, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 180,000 shares of the Company's common stock in connection with their emplo...
Landmark Bancorp, Inc. Announces Fourth Quarter Earnings Per Share of ...
Landmark Bancorp, Inc. Announces Fourth Quarter Earnings Per Share of $0.48 Declares Cash Dividend of $0.21 per Share Manhattan, KS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.48 for the three months ended December 31, 2023, compared to $0.53 per share in the third quarter of 2023 and $0.22 per share in the same quarter last year. Net earnings for the fourth quarter of 2023 amounted to $2.6 million, compared to $2.9 million in the prior quarter and $1.2 million for the fourth quarter of 2022. For the three...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.